Trial reportThe journal of headache and pain2022
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine.
Trial report in The journal of headache and pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Migraine in pediatric population: the role of biochemical markers.The journal of headache and pain · 2026Pooled it
- Pediatric migraine: Neurodevelopmental mechanisms, clinical phenotypes, and modern therapeutics.World journal of clinical pediatrics · 2026Review
- Exposure Matching Using Population Pharmacokinetic Modeling and Simulation to Support Rimegepant Dose Selection for Pediatric Patients With Migraine.Clinical and translational science · 2025Article
- Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system.The journal of headache and pain · 2025Article
- Effectiveness and Safety of CGRP-Targeted Therapies Combined with Lifestyle Modifications for Chronic Migraine in Korean Pediatric Patients: A Retrospective Study.Brain sciences · 2025Article
- Current Trends in Pediatric Migraine: Clinical Insights and Therapeutic Strategies.Brain sciences · 2025Review
- A Review of the Biochemical Diagnostic Biomarkers in Migraine: New Perspectives in Diagnostics.Pain research & management · 2025Review
- Calcitonin-Gene-Related Peptide in Migraine and Tension-Type Headache in Children During Interictal Period.Diagnostics (Basel, Switzerland) · 2024Article
- OTULIN's influence on neuroinflammation and pain modulation in trigeminal neuralgia.CNS neuroscience & therapeutics · 2024Article
- PACAP-38 and sex hormones in women with migraine: exploratory analysis of a cross-sectional, matched cohort study.The journal of headache and pain · 2024Article
- Untangling the mess of CGRP levels as a migraine biomarker: an in-depth literature review and analysis of our experimental experience.The journal of headache and pain · 2024Review
- Tryptophan metabolites and gut microbiota play an important role in pediatric migraine diagnosis.The journal of headache and pain · 2024Article
- From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment.Cells · 2023Review
- Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Observational
- Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system.Frontiers in pharmacology · 2023Article
- Pediatric Migraine: Diagnosis and Management.Journal of clinical medicine · 2022Article
- Female reproductive functions of the neuropeptide PACAP.Frontiers in endocrinology · 2022Review
- Article
- Can serum neuropeptide levels help diagnose pediatric migraine? A prospective case-control study.HeadacheArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn increasing number of studies have suggested that the important role of vasoactive peptides, such as pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) and calcitonin gene-related peptide (CGRP), in the pathophysiology of migraine seems undeniable in adults, but studies in pediatric migraine patients remain scarce. We prospectively investigated CGRP and PACAP-38 plasma levels in children with migraine during ictal and interictal periods and compared the results between migraine patients with aura and without aura. We were the first to explore the diagnostic value of a combination of CGRP and PACAP-38.
methodsSeventy-six migraine patients aged 4-18 years and seventy-seven age-matched healthy children were included in the study. Plasma vasoactive peptides were measured using the enzyme-linked immunosorbent assay (ELISA). Differences and correlations of groups were analyzed using the independent samples t-test, analysis of variance (ANOVA), Mann-Whitney U test, and multiple linear regression. We also performed logistic regression and receiver operating characteristic curve (ROC) analyses to evaluate the diagnostic value of CGRP and PACAP-38 in pediatric migraine.
resultsPACAP-38 and CGRP levels in migraine patients during the ictal and interictal periods were higher than those in controls (p < 0.001). PACAP-38 and CGRP levels in migraine patients with aura and without aura were higher than those in controls (p < 0.001). PACAP-38 and CGRP were independent risk factors in diagnosing pediatric migraine (adjusted OR (PACAP-38) =1.331, 95% CI: 1.177-1.506, p < 0.001; adjusted OR (CGRP) = 1.113, 95% CI: 1.064-1.165, p < 0.001). Area Under Curve (AUC) comparison: Combination (0.926) > CGRP (0.869) > PACAP-38 (0.867).
conclusionsOur study found almost the same changes in CGRP and PACAP levels in pediatric migraine, suggesting that CGRP and PACAP-38 may work together to play an integral role in pediatric migraine. Higher CGRP levels were found in the ictal phase than in the interictal phase and with aura group than without aura group, indicating that CGRP may take part in the formation of pain and aura. Moreover, ROC and logistic regression analyses suggested that CGRP and PACAP-38 are good indicators to diagnose pediatric migraine, and the combination of CGRP and PACAP-38 was valuable in diagnosing pediatric migraine and differentiating pediatric migraine from non-migraine headaches.
trial registrationThe study has been registered at the Chinese Clinical Trial Registry ( ChiCTR2100043157 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.